Compare MCD & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | NVS |
|---|---|---|
| Founded | 1940 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3B | 310.4B |
| IPO Year | 1995 | N/A |
| Metric | MCD | NVS |
|---|---|---|
| Price | $324.86 | $155.75 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 28 | 4 |
| Target Price | ★ $342.21 | $118.00 |
| AVG Volume (30 Days) | ★ 3.1M | 2.4M |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.27% | 1.92% |
| EPS Growth | ★ 4.92 | N/A |
| EPS | ★ 11.95 | N/A |
| Revenue | ★ $26,885,000,000.00 | N/A |
| Revenue This Year | $8.05 | $2.56 |
| Revenue Next Year | $5.72 | $4.91 |
| P/E Ratio | $27.49 | ★ $23.13 |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $283.47 | $97.72 |
| 52 Week High | $341.75 | $170.46 |
| Indicator | MCD | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 42.95 |
| Support Level | $320.15 | $113.19 |
| Resistance Level | $335.67 | $158.80 |
| Average True Range (ATR) | 4.74 | 2.44 |
| MACD | -1.57 | -1.63 |
| Stochastic Oscillator | 17.43 | 4.39 |
McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.